Dr. Miller is a Partner and Founder of Mediphase Venture Partners. He has invested in more than 25 private companies in life sciences/health care.

Prior to founding Mediphase Venture Partners, Dr. Miller was Senior Vice President, Hambrecht&Quist Capital Management in Boston from 1997-1999, where he was responsible for evaluating all private equity investments. Before joining H&Q, he was Executive Vice President and Director, Internal Operations at Avicenna Systems Corp from 1996 to 1997. Avicenna was acquired by Synetic, Inc. (now WebMD) in 1996.

From 1990 to 1996, Dr. Miller was Vice President at HPR, Inc. as the company underwent dramatic growth and a successful IPO in 1995. HPR was acquired by HBOC in 1997. Dr. Miller served as a Senior Scientist at the Health Data Institute, Inc. from 1985 to 1987. He has consulted extensively for major pharmaceutical companies, including Pfizer, Roche, Upjohn and Boehringer Ingelheim.

Dr. Miller is trained as a physician and pharmacologist and was a faculty member in the Department of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine in Boston. He has published more than 100 scientific papers, and received numerous awards in this field, including national awards from both major professional societies in clinical pharmacology. He is currently Adjunct Associate Professor of Pharmacology at Tufts and Instructor in Medicine at Harvard Medical School. Dr. Miller was educated at Harvard College, Cambridge University and Harvard Medical School, and completed his clinical training at the Massachusetts General Hospital in Boston. He is Board certified in Internal Medicine, Pulmonary Disease and Clinical Pharmacology.

Paul Howard is a Partner and founder of Mediphase Venture Partners. Mr. Howard concentrates his efforts on the Life Sciences companies in the portfolios. He has invested in over 25 private companies that include Tularik, Exelixis, CV Therapeutics, Cubist, Rosetta Inpharmatics, Dyax and LJL Biosytems. Mr. Howard serves on the Board of Directors of Supplemental Health Care and Serenex.

Prior to founding Mediphase Venture Partners, Mr. Howard was a Senior Vice President at Hambrecht & Quist Capital Management in Boston from 1992-1999, where he was responsible for managing the fund's biotechnology investments. From 1983-1990 Mr. Howard was a Senior Technical Sales Executive for the Miles Biotechnology Division of Bayer A.G.

Mr. Howard earned an A.B. from Bowdoin College in 1981, an M.S. from the University of Massachusetts, Amherst in 1983, and an S.M. from the Sloan School of Management at M.I.T. in 1992.

David Lubner joined Mediphase in 2006 as CFO. He has extensive experience in finance and operations at health care/life sciences companies. He served as CFO at PharMetrics from 1999-2006, managing the company’s successful acquisition by IMS Health. Previously he was CFO at ProScript, Inc., a biotechnology company, and controller at Immulogic Pharmaceutical Corp.

Mr. Lubner received a B.S. in Accounting from Northeastern University and an M.S. in Taxation from Bentley College. He is a C.P.A.

Mr. Gallivan is a Senior Partner in Mediphase Capital Partners. Previously, he was Senior Vice President of Sales and a member of the Executive Committee of Merck & Co., Inc. Mr. Gallivan retired from Merck in September 1998 after serving over 35 years in a wide variety of functional areas in both Canada and the United States. During his time in the United States, he had marketing responsibility for the blockbuster products Vasotec, Prilosec, Mevacor and Zocor.

As the Senior Vice President of Sales at Merck, he directed the selling effort through a period of significant expansion, increasing the size of the sales force by 40% to 5,000 representatives.

Mr. Gallivan is a founder and Board member of ImpactRx, a promotion response data provider serving the healthcare industry. He has served as a consultant to several pharmaceutical and biotechnology companies on marketing strategy and sales force deployment projects.

Ms. Cobb is responsible for investor relations, as well as all of the day-to-day operations of the office. Prior to joining Mediphase, she honed her organizational and multi-tasking skills over many years in the travel industry.

She received her B.A. in Semiotics from Brown University.

Eric Gordon, Ph.D., Chairman
Former Chief Scientific Officer, Sunesis, Inc., Senior positions in medicinal chemistry at Versicor, Affymax and Bristol-Myers Squibb

Julian Adams, Ph.D.
Senior Vice President Research & Development, Infinity Pharmaceuticals

Thomas J. Schuetz, M.D., Ph.D.
Former Chief Medical Officer, Therion Biologics

Timothy Macdonald, Ph.D.
Professor of Chemistry, University of Virginia




David Brook
Partner, Hamilton, Brook, Smith & Reynolds, P.C.